RETA
Income statement / Annual
Last year (2022), Reata Pharmaceuticals, Inc.'s total revenue was $2.22 M,
a decrease of 80.71% from the previous year.
In 2022, Reata Pharmaceuticals, Inc.'s net income was -$311.90 M.
See Reata Pharmaceuticals, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
FY-2013
|
| Period Ended |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
12/31/2013 |
| Operating Revenue |
$2.22 M |
$11.49 M |
$9.02 M |
$26.52 M |
$53.59 M |
$48.06 M |
$49.86 M |
$50.32 M |
$51.95 M |
$51.20 M |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$124.40 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$2.22 M
|
$11.49 M
|
$9.02 M
|
-$97.88 M
|
$53.59 M
|
$48.06 M
|
$49.86 M
|
$50.32 M
|
$51.95 M
|
$51.20 M
|
| Gross Profit Ratio |
1
|
1
|
1
|
-3.69
|
1
|
1
|
1
|
1
|
1
|
1
|
| Research and Development Expenses |
$169.84 M
|
$155.99 M
|
$159.08 M
|
$128.11 M
|
$97.29 M
|
$71.27 M
|
$39.45 M
|
$35.14 M
|
$34.31 M
|
$45.25 M
|
| General & Administrative Expenses |
$109.28 M
|
$99.00 M
|
$75.13 M
|
$58.30 M
|
$32.75 M
|
$23.26 M
|
$16.60 M
|
$13.69 M
|
$11.51 M
|
$13.40 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$109.28 M
|
$99.00 M
|
$75.13 M
|
$58.30 M
|
$32.75 M
|
$23.26 M
|
$16.60 M
|
$13.69 M
|
$11.51 M
|
$13.40 M
|
| Other Expenses |
$1.13 M
|
$1.20 M
|
$1.14 M
|
$932,000.00
|
$431,000.00
|
-$3,000.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$280.25 M
|
$256.20 M
|
$235.34 M
|
$187.34 M
|
$130.47 M
|
$94.97 M
|
$56.74 M
|
$50.65 M
|
$48.33 M
|
$61.58 M
|
| Cost And Expenses |
$280.25 M
|
$256.20 M
|
$235.34 M
|
$311.74 M
|
$130.47 M
|
$94.97 M
|
$56.74 M
|
$50.65 M
|
$48.33 M
|
$61.58 M
|
| Interest Income |
$5.99 M
|
$177,000.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$41.77 M
|
$53.25 M
|
$36.78 M
|
$11.20 M
|
$6.18 M
|
$1.45 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$1.13 M
|
$1.20 M
|
$1.14 M
|
$932,000.00
|
$431,000.00
|
$437,000.00
|
$682,000.00
|
$1.82 M
|
$2.51 M
|
$2.93 M
|
| EBITDA |
-$269.03 M |
-$243.51 M |
-$232.32 M |
-$278.03 M |
-$73.91 M |
-$46.48 M |
-$6.41 M |
$1.45 M |
$6.09 M |
-$7.49 M |
| EBITDA Ratio |
-121.4
|
-21.19
|
-24.97
|
-10.72
|
-1.43
|
-0.97
|
-0.13
|
0.03
|
0.12
|
-0.15
|
| Operating Income Ratio |
-121.91
|
-21.3
|
-25.09
|
-10.76
|
-1.43
|
-0.98
|
-0.14
|
-0.01
|
0.07
|
-0.2
|
| Total Other Income/Expenses Net |
-$33.89 M
|
-$53.13 M
|
-$43.91 M
|
-$4.94 M
|
-$3.64 M
|
-$1.19 M
|
$428,000.00
|
$32,000.00
|
$86,000.00
|
$36,000.00
|
| Income Before Tax |
-$311.93 M
|
-$297.84 M
|
-$270.24 M
|
-$290.16 M
|
-$80.52 M
|
-$47.67 M
|
-$6.67 M
|
-$302,000.00
|
$3.67 M
|
-$10.35 M
|
| Income Before Tax Ratio |
-140.76
|
-25.92
|
-29.96
|
-10.94
|
-1.5
|
-0.99
|
-0.13
|
-0.01
|
0.07
|
-0.2
|
| Income Tax Expense |
-$25,000.00
|
-$450,000.00
|
-$22.49 M
|
$8,000.00
|
$26,000.00
|
$3,000.00
|
-$441,000.00
|
$1.15 M
|
$2.98 M
|
$24.76 M
|
| Net Income |
-$311.90 M
|
-$297.39 M
|
-$247.75 M
|
-$290.17 M
|
-$80.55 M
|
-$47.67 M
|
-$6.23 M
|
-$1.45 M
|
$689,000.00
|
-$35.11 M
|
| Net Income Ratio |
-140.75
|
-25.88
|
-27.47
|
-10.94
|
-1.5
|
-0.99
|
-0.12
|
-0.03
|
0.01
|
-0.69
|
| EPS |
-8.59 |
-8.19 |
-7.35 |
-9.54 |
-2.91 |
-1.99 |
-0.31 |
-0.26 |
0.13 |
-6.38 |
| EPS Diluted |
-8.59 |
-8.19 |
-7.35 |
-9.54 |
-2.91 |
-1.99 |
-0.31 |
-0.26 |
0.0345 |
-1.76 |
| Weighted Average Shares Out |
$36.32 M
|
$36.32 M
|
$33.71 M
|
$30.41 M
|
$27.70 M
|
$23.93 M
|
$19.82 M
|
$5.50 M
|
$5.50 M
|
$5.50 M
|
| Weighted Average Shares Out Diluted |
$36.32 M
|
$36.32 M
|
$33.71 M
|
$30.41 M
|
$27.70 M
|
$23.93 M
|
$19.82 M
|
$5.50 M
|
$20.00 M
|
$20.00 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
